HCG Gains Majority Control of Kenyan Diagnostic Entity

Healthcare Global (Kenya) Private Limited has increased its stake in Advanced Molecular Imaging Limited (AMIL) from 50% to 50.10%.

The transaction, completed on October 5, 2026, involved a cash consideration of 42,150 Kenyan Shillings (approximately INR 31,288).

Reader Takeaway

This shift to subsidiary status grants HCG consolidated control in Kenya; the capital outlay is financially immaterial.

What just happened

Healthcare Global (Kenya) Private Limited, a step-down subsidiary of HCG, acquired 10 additional ordinary shares of AMIL from Meditec Systems Limited. This move takes HCG’s holding across the 50% threshold, officially reclassifying AMIL from an associate company to a subsidiary within the group’s corporate structure.

Why this matters

While the financial investment is negligible, the reclassification allows HCG to exercise greater operational and financial control over the Kenyan diagnostic imaging business. As AMIL recorded a turnover of 156.28 million Kenyan Shillings (approx. INR 10.96 crore) for the financial year ending December 31, 2025, bringing it under the subsidiary umbrella streamlines HCG's international reporting and strategic execution in the East African market.

Context

Advanced Molecular Imaging Limited is a Kenya-based entity founded in 2016. It specializes in molecular and diagnostic imaging services, a core segment of HealthCare Global’s service offerings. The transaction marks a tactical move to consolidate assets in an emerging market.

What to track next

Investors should monitor how the integration of AMIL as a subsidiary impacts the consolidated financial statements of the parent company, HealthCare Global Enterprises, in upcoming quarters.